The Trends, Clinicopathological Features, and Treatment Outcomes of Patients with Prostate Cancer in Lokoja, Nigeria

Author:

Ogunmola Ayodeji Olusola1,Oyedeji Adedayo S.A.1,Fadahunsi Oluseyi O.2,Awelimabor Daniel I.2,Osunaiye Olutayo I.1,Aisuodionoe-Shadrach Oseremen I.3

Affiliation:

1. Urology Unit, Department of Surgery, Federal Teaching Hospital, Lokoja, Kogi State, Nigeria

2. Department of Anatomic Pathology and Histopathology, Federal Teaching Hospital, Lokoja, Kogi State, Nigeria

3. Division of Urology, Department of Surgery, College of Health Sciences, University of Abuja, Abuja, Nigeria

Abstract

Abstract Background: Prostate cancer (PCa) was the most common noncutaneous cancer among Nigerian men in 2020. Despite this high incidence, documented rates may be an underestimation. Objectives: This study aimed to determine the hospital incidence rate, trends, and characterise the clinicopathologic features, and treatment outcomes of patients with PCa in our institution. Materials and Methods: A 5-year retrospective review of patients managed for PCa at the Federal Teaching Hospital, Lokoja (FTHL), Nigeria, from 2016 to 2020. Medical abstraction was done on clinicopathologic features, treatment received, serum prostate specific antigen (PSA) at diagnosis, 3, and 7 months of androgen deprivation therapy (ADT). Data obtained were analysed using SPSS 25, and trends analysis of the annual incidence rate and number of patients with PCa in the period was done using joinpoint regression modelling. Results: Of 89 patients, 83 had complete medical records. The average annual hospital incidence rate was 174/100,000, and the mean age at diagnosis was 70.4 years. Locally advanced disease was found in 81.9% of patients, and tumours were ISUP grade groups 4 and 5 in 54.2% of patients. ADT was done in 62.6% of the patients, while 28.9% of the patients defaulted after diagnosis. The mean serum PSA was 71.9 ng/mL (7.7–156) at diagnosis and was 11.1 ng/mL (0.1–102) and 15.3 ng/mL at 3 and 7 months of ADT, respectively. Only 40.6% of the treated patients had a serum PSA ≤ 4 ng/mL at 7 months of ADT. Conclusions: Patients with PCa in FTHL, Nigeria, have mostly locally advanced disease at diagnosis. Over half have a high-grade pattern and fail to achieve a serum PSA ≤ 4 ng/mL after 7 months of ADT.

Publisher

Medknow

Reference21 articles.

1. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. The epidemiology of prostate cancer;Pernar;Cold Spring Harb Perspect Med,2018

3. Quality of evidence on prostate cancer in Nigeria;Fatiregun;Cancer Health Disparit,2019

4. Emergent trends in the reported incidence of prostate cancer in Nigeria;Ifere;Clin Epidemiol,2012

5. Histopathological review of prostate cancer in Lokoja, Nigeria;Oluwole;Infect Agent Cancer,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3